Saratoga Research & Investment Management reduced its stake in Becton Dickinson and Co. (NYSE:BDX) by 3.2% during the second quarter, Holdings Channel reports. The institutional investor owned 252,660 shares of the company’s stock after selling 8,380 shares during the period. Becton Dickinson and comprises about 3.8% of Saratoga Research & Investment Management’s portfolio, making the stock its 11th largest position. Saratoga Research & Investment Management’s holdings in Becton Dickinson and were worth $42,849,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Bank of Montreal Can purchased a new position in shares of Becton Dickinson and during the second quarter valued at approximately $118,746,000. UBS Group AG increased its position in Becton Dickinson and by 52.8% in the first quarter. UBS Group AG now owns 1,345,361 shares of the company’s stock worth $204,253,000 after buying an additional 464,650 shares during the last quarter. Bellevue Group AG bought a new position in Becton Dickinson and during the first quarter worth about $15,216,000. Huntington National Bank increased its position in Becton Dickinson and by 181.7% in the second quarter. Huntington National Bank now owns 133,893 shares of the company’s stock worth $22,707,000 after buying an additional 86,365 shares during the last quarter. Finally, AXA increased its position in Becton Dickinson and by 18.8% in the first quarter. AXA now owns 348,007 shares of the company’s stock worth $52,835,000 after buying an additional 55,178 shares during the last quarter. 81.85% of the stock is owned by institutional investors and hedge funds.
Shares of Becton Dickinson and Co. (NYSE:BDX) traded up 0.88% on Tuesday, reaching $173.05. 439,660 shares of the company were exchanged. Becton Dickinson and Co. has a 52 week low of $129.50 and a 52 week high of $181.76. The firm’s 50 day moving average price is $176.29 and its 200 day moving average price is $170.04. The stock has a market capitalization of $36.85 billion, a price-to-earnings ratio of 33.02 and a beta of 0.93.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 4th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.21 by $0.14. Becton Dickinson and had a net margin of 9.24% and a return on equity of 24.26%. The business earned $3.20 billion during the quarter, compared to analyst estimates of $3.21 billion. During the same quarter in the previous year, the business posted $2.05 EPS. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. Equities research analysts anticipate that Becton Dickinson and Co. will post $8.56 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, September 30th. Stockholders of record on Friday, September 9th were issued a $0.66 dividend. The ex-dividend date was Wednesday, September 7th. This represents a $2.64 annualized dividend and a dividend yield of 1.54%. Becton Dickinson and’s dividend payout ratio is currently 50.19%.
BDX has been the subject of a number of research reports. Bank of America Corp. reissued a “buy” rating on shares of Becton Dickinson and in a research note on Tuesday, July 12th. Zacks Investment Research downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. Jefferies Group increased their price target on shares of Becton Dickinson and from $190.00 to $192.00 and gave the stock a “buy” rating in a research note on Thursday, July 28th. Leerink Swann reissued a “hold” rating on shares of Becton Dickinson and in a research note on Tuesday, August 9th. Finally, Cowen and Company reissued an “outperform” rating and issued a $185.00 price target on shares of Becton Dickinson and in a research note on Tuesday, August 16th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $170.82.
In other news, insider Linda M. Tharby sold 11,704 shares of the business’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $177.27, for a total value of $2,074,768.08. Following the completion of the sale, the insider now owns 22,146 shares in the company, valued at approximately $3,925,821.42. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gary M. Cohen sold 29,367 shares of the business’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $176.81, for a total transaction of $5,192,379.27. Following the completion of the sale, the insider now owns 125,870 shares of the company’s stock, valued at approximately $22,255,074.70. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co. (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co. and related companies with MarketBeat.com's FREE daily email newsletter.